Skip to main content

Table 1 Patient characteristics, clinical status, and therapies

From: Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

Patient Number Study Druga HIV-1 Status Age (years) Baseline Weight (kg) No. Lung Fields Involvedb Medicationc
Thailand       
1 t + 43 48.0 6 Rifater, E
2 t + 51 49.0 4 Rifater, E
3 t 32 43.0 4 Rifater, E
4 t 65 40.5 4 Rifater, E
5 t 46 43.3 4 Rifater, E
6 t + 60 41.3 4 RPE
7 t 31 52.8 1 RIP
8 t + 38 48.3 2 Rifater, E
9 t 25 56.5 3 Rifater, E
10 t + 25 49.5 1 Rifater, E
11 t + 49 44.5 3 Rifater, E
12 t 38 50.5 2 Rifater, E
13 P 25 40.0 2 Rifater, E
14 P 53 50.0 4 Rifater, E
15 t 55 52.0 5 Rifater, E
16 P 64 49.0 5 Rifater, E
17 t 22 42.0 1 Rifater, E
18 P 46 63.3 1 Rifater, E
19 t 63 71.0 3 Rifater, E
20 P 42 58.0 NA Rifater, E
New York       
21 t + 44 63.3 1 RIPE + Anti retroviral
22 t + 37 71.0 2 RIPE + Anti retroviral
23 P + 33 77.7 1 RIPE + Anti retroviral
24 P + 45 76.5 3 RIPE + Anti retroviral
25 t;t;p;t 32 53.7 3 RIPE
26 t;t + 35 66.5 2 RIPE + Anti retroviral
27 t;t + 30 63.3 3 RIPE + Anti retroviral
28 t;t;p;t 38 74.5 3 RIPE + CIP¶+ ETH¶
29 p;t;t + 42 83.8 1 RIPE + Anti retroviral
30 t;p;t;p 46 89.6 2 RIPE
  1. NA, not available; R, Rifampin; I, Isoniazid; P, Pyrazinamide; E, Ethambutol; CIP¶, Cipro for 16 days; ETH¶, Ethionamide for 16 days.
  2. aPatients received either thalidomide (t), placebo (p), or multiple cycles of t or p in the sequence shown.
  3. bInfiltration, granulomas, or cavities present on chest X-ray: a total of six lung fields were evaluated and results given for each patient.
  4. cRlifater, Rifampin isoniazid pyrazinamide.